KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma. PMID 39630057 · Blood · 2025-Feb-27 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020. PMID 40010775 · J Immunother Cancer · 2025-Feb-25 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer. PMID 40010771 · J Immunother Cancer · 2025-Feb-25 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Tislelizumab plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy for elderly patients with inoperable locally advanced esophageal squamous cell carcinoma: a multicenter, randomized, parallel-controlled, phase II clinical trial. PMID 40001034 · BMC Cancer · 2025-Feb-25 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Digital Therapeutics-Based Cardio-Oncology Rehabilitation for Lung Cancer Survivors: Randomized Controlled Trial. PMID 39999435 · JMIR Mhealth Uhealth · 2025-Feb-25 The study is a randomized controlled trial in human lung cancer survivors, but it evaluates a non-drug digital therapeutics-based telerehabilitation intervention and its primary endpoints are cardiopulmonary fitness (e.g., VO2 peak) and quality of life, not a time-to-event efficacy endpoint like OS, PFS, DFS, etc. Therefore, it does not meet the drug intervention or time-to-event endpoint criteria for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Nivolumab and hypofractionated radiotherapy in patients with advanced melanoma: A phase 2 trial. PMID 39864364 · Eur J Cancer · 2025-Feb-25 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials. PMID 39826197 · Eur J Cancer · 2025-Feb-25 The record is a pooled analysis across age subgroups from three randomized trials, not the primary result report of a single Phase III trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia. PMID 39626287 · Blood Adv · 2025-Feb-25 The study is an oncology randomized Phase 3 trial with drug intervention and original results, but the reported analysis is an ad hoc investigation of peripheral neuropathy symptom resolution and quality of life. It does not report a primary or key secondary time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, or associated Kaplan-Meier/HR statistics. Therefore, it is ineligible for the KM digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUM. PMID 39602342 · Blood Adv · 2025-Feb-25 The record describes a prespecified analysis from a randomized, phase-3 trial (FORUM) evaluating drug-containing conditioning regimens for allo-HSCT in pediatric ALL. It reports primary time-to-event efficacy endpoints (OS, EFS) and is an original result publication.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 1 Figure · 6 Panel · risk visible
Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma. PMID 39994363 · Sci Rep · 2025-Feb-24 The record describes a Phase II/III randomized trial (implied by the definitive comparison and primary efficacy reporting in a completed study, despite not explicitly stating the phase in the abstract) comparing two drug-containing regimens for multiple myeloma, with PFS and OS as primary endpoints. All eligibility criteria are met.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 1 Figure · 2 Panel · risk not_visible
Effect of adaptive variable-resistance training on chemotherapy-induced sarcopenia, fatigue, and functional restriction in pediatric survivors of acute lymphoblastic leukemia: a prospective randomized controlled trial. PMID 39985582 · Support Care Cancer · 2025-Feb-22 This is a randomized controlled trial of a non-drug intervention (exercise) in pediatric ALL survivors. While it involves patients with a human malignant neoplasm and is a prospective randomized trial, it does not meet the core eligibility criteria: 1) It is not a Phase III/IIIb or Phase II/III trial (no phase specified in metadata, likely an early-phase or single-center trial), and 2) The primary efficacy endpoints are not time-to-event (e.g., OS, PFS) but are functional, morphological, and patient-reported outcomes measured at baseline and post-intervention. The drug intervention criterion is met only peripherally as patients are 'cancer survivors' who have completed chemotherapy, but the trial itself tests an exercise intervention, not a drug therapy. Therefore, it is ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Single- versus multi-fraction spine stereotactic radiosurgery (ALL-STAR) for patients with spinal metastases: a randomized phase III trial protocol. PMID 39984889 · BMC Cancer · 2025-Feb-21 方案论文未报告临床试验结果。
H B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Effects of transcutaneous auricular vagus nerve stimulation on postoperative delirium in older patients with hip fracture: protocol for a randomised controlled trial. PMID 39979049 · BMJ Open · 2025-Feb-20 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Telpegfilgrastim for chemotherapy-induced neutropenia in breast cancer: A multicenter, randomized, phase 3 study. PMID 39820410 · Chin Med J (Engl) · 2025-Feb-20 Metadata (title) explicitly indicates a randomized phase 3 trial with a drug intervention for an oncology population. However, the primary endpoint is not specified as a time-to-event efficacy endpoint (e.g., OS, PFS); it appears to focus on neutropenia (a supportive care/safety outcome). The abstract is unavailable, preventing confirmation of a key efficacy endpoint, time-to-event analysis, or original result status.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial. PMID 39556780 · J Clin Oncol · 2025-Feb-20 The record describes a randomized trial with a drug intervention and OS as the primary time-to-event endpoint. However, the provided metadata (publication types, mesh, abstract) does not explicitly confirm the trial phase as Phase III/IIIb or Phase II/III, which is required for eligibility. The deterministic review flagged 'phase3_evidence_unclear'. Without explicit phase information, a definitive eligibility determination cannot be made.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy. PMID 39441941 · Blood · 2025-Feb-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Time to return of bowel function following perioperative probiotics in colorectal cancer surgery (PICCS-1): study protocol for a randomized controlled trial. PMID 39972354 · Trials · 2025-Feb-19 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Targeting autophagy in platinum-sensitive relapsed ovarian cancer: randomized phase II trial of hydroxychloroquine with chemotherapy with biomarker correlation. PMID 39969689 · Discov Oncol · 2025-Feb-19 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
6-mm vs 10-mm diameter fully covered self-expandable metal stents in patients with unresectable malignant distal bile duct stricture (COSMIC UNISON): study protocol for a multicenter, randomized controlled trial. PMID 39966935 · Trials · 2025-Feb-18 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Evaluating a digital prehabilitation tool in patients with colorectal surgery: protocol for a multisite randomised controlled trial. PMID 39965940 · BMJ Open · 2025-Feb-18 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Neoadjuvant immunotherapy with or without chemotherapy in locally advanced oral squamous cell carcinoma: Randomized, two-arm, phase 2 trial. PMID 39889711 · Cell Rep Med · 2025-Feb-18 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effects of a Targeted Concurrent Training Program on the Exercise Adherence in Female Breast Cancer Survivors: A Randomized Controlled Trial. PMID 39997304 · Healthcare (Basel) · 2025-Feb-17 The record describes a randomized controlled trial in breast cancer survivors, but the intervention is a physical activity program (non-drug). There is no drug-containing intervention. The primary outcome is physical activity time/intensity, not a time-to-event efficacy endpoint (e.g., OS, PFS). There is no evidence of Phase III or definitive trial design. Therefore, it does not meet the core eligibility criteria for a drug-containing oncology trial with a time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparative analysis of intestinal tumor segmentation in PET CT scans using organ based and whole body deep learning. PMID 39962481 · BMC Med Imaging · 2025-Feb-17 The record is an original comparative study from a phase III randomized trial (NCT01287741) in oncology (lymphoma). However, it is not eligible because (1) it does not involve a drug intervention—it compares deep learning image segmentation methods—and (2) it does not report a time-to-event efficacy endpoint (e.g., OS, PFS). The primary outcomes are segmentation performance metrics (Dice score, precision, recall, F1-score).
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Randomized controlled trial on the efficacy of topical urea-based cream in preventing capecitabine-associated hand-foot syndrome. PMID 39962445 · BMC Cancer · 2025-Feb-17 The study is a randomized, Phase II/III trial in oncology with a drug intervention, but it evaluates the prevention of a treatment-related adverse event (hand-foot syndrome) as its primary efficacy endpoint. It does not report a time-to-event efficacy endpoint such as overall survival, progression-free survival, or disease-free survival with Kaplan-Meier curves or hazard ratios. Therefore, it does not meet the key inclusion criterion for a Kaplan-Meier digitization cohort.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The LYMPH trial: comparing microsurgical with conservative treatment for chronic breast cancer-associated lymphoedema - study protocol of a pragmatic randomised international multicentre superiority trial. PMID 39961719 · BMJ Open · 2025-Feb-17 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Opioid-free versus opioid-based anaesthesia for free-flap reconstruction surgery of the breast: protocol for a phase III, multicentre, randomised controlled study. PMID 39961716 · BMJ Open · 2025-Feb-17 方案论文未报告临床试验结果。
H B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Maintenance therapy with the FMS-like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS-like tyrosine kinase 3-internal tandem duplication acute myeloid leukemia: A phase 2 study. PMID 39945223 · Cancer · 2025-Feb-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Chemotherapy dose density is prognostic for overall survival in patients with resectable pancreas cancer: A landmark analysis of SWOG 1505. PMID 39932777 · Cancer · 2025-Feb-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Update on safety and feasibility of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer. PMID 39921852 · Cancer · 2025-Feb-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy of cannabinoids for the prophylaxis of chemotherapy-induced nausea and vomiting-a systematic review and meta-analysis. PMID 39953210 · Support Care Cancer · 2025-Feb-14 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial. PMID 39952926 · Nat Commun · 2025-Feb-14 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Correlation of PSA and survival in metastatic hormone-sensitive prostate cancer treated with rezvilutamide plus ADT in the CHART trial. PMID 39419035 · Med · 2025-Feb-14 The record describes an exploratory analysis (correlation of PSA and survival) from the CHART trial, which is a randomized controlled trial in metastatic hormone-sensitive prostate cancer. While it is oncology, human, randomized, drug-intervention, and reports time-to-event efficacy data, the phase of the trial is not explicitly stated in the provided metadata. The deterministic review also flagged 'phase3_evidence_unclear'. Therefore, the phase criterion cannot be definitively established as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
[Heat-sensitive moxibustion assisted in palliative treatment to improve the quality of life in elderly patients with malignant tumor: a randomized controlled trial]. PMID 39943757 · Zhongguo Zhen Jiu · 2025-Feb-12 The study is an oncology randomized controlled trial with original results, but it is excluded because it does not meet key eligibility criteria: the trial phase is not stated (cannot confirm Phase III/IIIb or Phase II/III), the intervention is non-drug (moxibustion), and the primary efficacy endpoint is quality of life, not a time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Dexamethasone as an adjuvant with ropivacaine in thoracoscopy guided thoracic paravertebral block for postoperative analgesia in thoracic surgery. PMID 39934398 · Sci Rep · 2025-Feb-11 The study is a randomized trial in thoracic surgery patients with lung cancer, but it is not a definitive (Phase III/IIIb or Phase II/III) oncology trial. The intervention is an analgesic adjuvant (dexamethasone with ropivacaine) for postoperative pain management, not a systemic anticancer drug. The endpoints are postoperative pain scores, analgesic consumption, and recovery metrics, not time-to-event oncology efficacy outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Dynamics of molecular heterogeneity in high-risk luminal breast cancer-From intrinsic to adaptive subtyping. PMID 39933898 · Cancer Cell · 2025-Feb-10 The record describes a biomarker/subgroup analysis from a Phase III randomized trial (Penelope-B) but does not report the trial's primary or secondary time-to-event efficacy results for the drug intervention. It focuses on molecular heterogeneity and prognosis, not on evaluating the efficacy of the therapeutic intervention itself.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Health-related Quality of Life and hospital costs of Finnish melanoma patients participating in the second Multicenter Selective Lymphadenectomy Trial (MSLT-II). PMID 39930784 · Acta Oncol · 2025-Feb-10 The record describes a health-related quality of life and cost analysis from a randomized Phase III melanoma trial (MSLT-II). However, the intervention is a surgical procedure (complete lymph node dissection), not a drug-containing intervention. The primary endpoint is health-related quality of life, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). Therefore, it does not meet the eligibility criteria for a drug-containing oncology trial with a time-to-event primary/key secondary endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Low & Anaplastic Grade Glioma Umbrella Study of MOlecular Guided TherapieS (LUMOS-2): study protocol for a phase 2, prospective, multicentre, open-label, multiarm, biomarker-directed, signal-seeking, umbrella, clinical trial for recurrent IDH mutant, grade 2/3 glioma. PMID 39929517 · BMJ Open · 2025-Feb-10 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
JCCG ALL-B12: Evaluation of Intensified Therapies With Vincristine/Dexamethasone Pulses and Asparaginase and Augmented High-Dose Methotrexate for Pediatric B-ALL. PMID 39531610 · J Clin Oncol · 2025-Feb-10 The record meets most criteria (oncology, human, randomized, drug intervention, time-to-event endpoint, original result) but the explicit trial phase (Phase III/IIIb or Phase II/III) is not established in the provided metadata. Therefore, the 'phase3_or_definitive' criterion cannot be set to true, making the overall eligibility false.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial. PMID 39423355 · J Clin Oncol · 2025-Feb-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
OPAR: A Randomized Trial of Partial Breast Irradiation in Five Fractions Once Daily for Early Breast Cancer. PMID 39378393 · J Clin Oncol · 2025-Feb-10 The study is an oncology randomized trial reporting original results, but it is a Phase II trial (not Phase III/IIIb or definitive Phase II/III), does not involve a drug intervention (only radiation therapy), and does not have a primary or key secondary time-to-event efficacy endpoint (primary endpoint is adverse cosmesis; secondary endpoints include toxicity, not OS/PFS/DFS/EFS/RFS/TTP).
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Stereotactic radiosurgery for 1-10 brain metastases to avoid whole-brain radiotherapy: Results of the CYBER-SPACE randomized phase 2 trial. PMID 39340439 · Neuro Oncol · 2025-Feb-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Online Radiotherapy: The Paradigm Shift to Real-Time Adaptive Radiotherapy. PMID 39705230 · Dtsch Arztebl Int · 2025-Feb-07 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
A comparative study of mitoxantrone hydrochloride injection and technetium-99 m for tracing axillary sentinel nodes in patients with breast cancer. PMID 39915736 · BMC Cancer · 2025-Feb-06 The record is an ancillary analysis of a Phase III trial evaluating a diagnostic tracer (mitoxantrone hydrochloride) for sentinel lymph node detection in breast cancer. It meets criteria for oncology, human, Phase III, drug intervention, and original result. However, it lacks any time-to-event efficacy endpoint (OS, PFS, DFS, etc.), is not described as randomized, and is a secondary analysis rather than a primary efficacy report. Therefore, it is ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Safety of a short-term infusion of fosnetupitant in patients with gastrointestinal and breast cancer: a prospective study. PMID 39265970 · Oncologist · 2025-Feb-06 The record is an original, prospective, single-arm Phase II trial of a drug (fosnetupitant). It is human and oncology. However, it is excluded because it is non-randomized, not a Phase III/IIIb or Phase II/III trial, and its primary and secondary endpoints are safety measures and complete response rate, not a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS).
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
HER-SAFE study design: an open-label, randomised controlled trial to investigate the safety of withdrawal of pharmacological treatment for recovered HER2-targeted therapy-related cardiac dysfunction. PMID 39909533 · BMJ Open · 2025-Feb-05 This is a protocol for a randomized trial investigating the safety of withdrawing heart failure medication in cancer survivors. It lacks results, does not report a Phase III/IIIb or definitive Phase II/III trial, does not include a drug intervention for the cancer, and its primary endpoint is a safety/clinical outcome, not a time-to-event efficacy endpoint like OS or PFS.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of NeoAdjuvant chemotherapy with or without tIslelizumab followed by debulking surgery for oVarian cancEr (NAIVE study) in China: study protocol of an open-label, phase II, randomised controlled trial. PMID 39909529 · BMJ Open · 2025-Feb-05 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Effect of intermittent urethral catheter clamping combined with active urination training (ICCAUT) strategy on postoperative urinary dysfunction after radical rectal cancer surgery: single-centre randomised controlled trial (ICCAUT -1) study protocol. PMID 39909516 · BMJ Open · 2025-Feb-05 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
A new treatment strategy for mid-low rectal cancer patients exhibiting a clinical complete or near-complete response to neoadjuvant chemoradiotherapy: Transanal endoscopic microsurgery --A multicenter prospective case-control clinical trial by MONT-R. PMID 39693893 · Eur J Cancer · 2025-Feb-05 The study is a randomized, prospective, multicenter trial with human oncology patients and time-to-event efficacy endpoints (DFS, OS). However, the intervention is a surgical procedure (TEM) versus radical surgery, with no drug-containing intervention. The trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata, and the intervention is non-pharmacologic. Therefore, it fails the drug-intervention requirement and lacks definitive Phase III evidence.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Can metformin prevent cancer relative to sulfonylureas? A target trial emulation accounting for competing risks and poor overlap via double/debiased machine learning estimators. PMID 39030720 · Am J Epidemiol · 2025-Feb-05 The record describes an observational pharmacoepidemiologic study (target trial emulation) comparing metformin to sulfonylureas for cancer incidence in a diabetes cohort. It is not a randomized clinical trial, not a Phase II/III study, and does not report a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) in an oncology therapeutic context. The endpoint is cancer incidence, which is a prevention outcome, not a therapeutic efficacy endpoint in a malignant neoplasm trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Collagen turnover biomarkers to predict outcome of patients with biliary cancer. PMID 39905306 · BMC Gastroenterol · 2025-Feb-04 While the record is from a randomized oncology study with human participants and time-to-event endpoints, it is ineligible because it does not provide evidence of a Phase III/IIIb or Phase II/III trial, does not specify a drug-containing intervention, and is a biomarker analysis report rather than the formal efficacy report of a randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -